Lotilaner Ophthalmic Solution 0.25%: First Approval

Demodex Blepharitis: A Comprehensive Review of the Disease, Current Management, and Emerging Therapies

(2023) Michelle K. Rhee et al.   Eye & Contact Lens-Science and Clinical Practice

Lotilaner Ophthalmic Solution, 0.25% for Demodex Blepharitis: Randomized, Vehicle-Controlled, Multicenter, Phase 3 Trial (Saturn-2)

(2023) Ian Benjamin Gaddie et al.   OPHTHALMOLOGY

Delphi Panel Consensus Regarding Current Clinical Practice Management Options for Demodex blepharitis

(2023) Marjan Farid et al.   Clinical Ophthalmology

Lotilaner Ophthalmic Solution, 0.25%, for the Treatment of Demodex Blepharitis: Results of a Prospective, Randomized, Vehicle-Controlled, Double-Masked, Pivotal Trial (Saturn-1)

(2022) Elizabeth Yeu et al.   CORNEA

Treatment of Demodex Blepharitis: A Prospective, Randomized, Controlled, Double-Masked Clinical Trial Comparing Topical Lotilaner Ophthalmic Solution, 0.25% Eyedrops to Vehicle

(2022) Elizabeth Yeu et al.   OCULAR IMMUNOLOGY AND INFLAMMATION

Current review of isoxazoline ectoparasiticides used in veterinary medicine

(2021) Xueying Zhou et al.   JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS

Collarette Elimination and Demodex Mite Eradication with Topical Lotilaner Ophthalmic Solution, 0.25%

(2021) Roberto Gonzalez-Salinas et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Safety and efficacy of lotilaner ophthalmic solution, 0.25% for the treatment of blepharitis due to demodex infestation: A randomized, controlled, double-masked clinical trial

(2021) Roberto Gonzalez-Salinas et al.   Contact Lens & Anterior Eye

Safety and Efficacy of Topical Lotilaner Ophthalmic Solution 0.25% for the Treatment of Demodex Blepharitis: A Pilot Study

(2021) Roberto Gonzalez-Salinas et al.   Journal of Ophthalmology

The antiparasitic isoxazoline A1443 is a potent blocker of insect ligand-gated chloride channels

(2009) Yoshihisa Ozoe et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS